Modified EPA Compound Lowers Very High Triglycerides and Improves Blood Sugar Markers in Early Trial
This clinical trial tested NST-1024, a lab-modified version of EPA (the omega-3 fatty acid found in fish oil), in people with very severe triglyceride elevations (levels between 500 and 2000 mg/dL). The goal was to see if this altered EPA molecule could lower triglycerides more effectively than standard EPA while also supporting healthy blood sugar levels.
Over 44 participants were randomly assigned to take either NST-1024 or a placebo twice daily for four weeks. Those taking NST-1024 saw their triglycerides drop by about 36%, compared to a 9% drop in the placebo group — a meaningful difference. The treatment group also saw a small but significant rise in HDL (‘good’) cholesterol, with no major changes in LDL cholesterol or apolipoprotein B levels.
Interestingly, the NST-1024 group also showed improvements in fasting blood sugar and a marker called C-peptide, which relates to insulin production, suggesting possible effects beyond just lipid levels.
What this means for you
This early-stage (phase 2) trial suggests that a chemically modified form of EPA may help lower extremely high triglycerides and support healthy blood sugar markers more than a placebo did, but this was a small, short study and larger trials are needed before drawing firm conclusions about everyday omega-3 or EPA supplements.
Ready to start? The ALP Protocol delivers the EPA & DHA doses used in the research.
Start the ALP ProtocolSource
Journal of clinical lipidology · 2026-09-29 · DOI: 10.1016/j.jacl.2026.09.016
Read the original source ↗This summary is for educational purposes only and is not medical advice. Always talk to your healthcare provider before making changes to your supplement routine.